[1] LIVERMORE D M. Has the era of untreatable infections arrived?[J].J Antimicrob Chemother, 2009, 64(S1):i29-i36.
[2] SUÁREZ C, PEÑA C, TUBAU F, et al. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections[J].J Infect, 2009, 58(4):285-290.
[3] 韩伟, 张铁, 王春光, 等.大肠埃希菌耐药机制研究进展[J].动物医学进展, 2006, 27(1):51-53.
HAN W, ZHANG T, WANG C G, et al. Progress on the drug resistance of Escherichia coli[J].Progress in Veterinary Medicine, 2006, 27(1):51-53. (in Chinese)
[4] VAN DEN BOGAARD A E, WILLEMS R, LONDON N, et al. Antibiotic resistance of faecal enterococci in poultry,poultry farmers and poultry slaughterers[J].J Antimicrob Chemother, 2002, 49(3):497-505.
[5] VANTARAKIS A, VENIERI D, KOMNINOU G, et al.Differentiation of faecal Escherichia coli from humans and animals by multiple antibiotic resistance analysis[J]. Lett Appl Microbiol, 2006, 42(1):71-77.
[6] ZAPUN A, CONTRERAS-MARTEL C, VERNET T. Penicillin-binding proteins and β-lactam resistance[J].FEMS Microbiol Rev, 2008, 32(2):361-385.
[7] 熊亚莉, 范昕建.青霉素结合蛋白研究进展[J].国外医药(抗生素分册), 2004, 25(5):193-197.
XIONG Y L, FAN X J. Research progress of penicillin binding protein[J].Foreign Medicine (Antibiotic Partition), 2004, 25(5):193-197. (in Chinese)
[8] CHEN W, ZHANG Y M, DAVIES C. Penicillin-binding protein 3 is essential for growth of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 2017, 61(1):1616-1651.
[9] PEPPER E D, FARRELL M J, FINKEL S E. Role of penicillin-binding protein 1b in competitive stationary-phase survival of Escherichia coli[J].FEMS Microbiol Lett, 2006, 263(1):61-67.
[10] MEBERG B M, PAULSON A L, PRIYADARSHINI R, et al. Endopeptidase penicillin-binding proteins 4 and 7 play auxiliary roles in determining uniform morphology of Escherichia coli[J]. J Bacteriol, 2004, 186(24):8326-8336.
[11] NELSON D E, YOUNG K D. Penicillin binding protein 5 affects cell diameter, contour, and morphology of Escherichia coli[J]. J Bacteriol, 2000, 182(6):1714-1721.
[12] GHOSH A S, YOUNG K D. Sequences near the active site in chimeric penicillin binding proteins 5 and 6 affect uniform morphology of Escherichia coli[J].J Bacteriol, 2003, 185(7):2178-2186.
[13] ZERVOSEN A, SAUVAGE E, FRōRE J M, et al. Development of new drugs for an old target-the penicillin binding proteins[J]. Molecules (Basel, Switzerland), 2012, 17(12):12478-12505.
[14] JUAN C, MACIÁ M D, GUTIÉRREZ O, et al. Molecular mechanisms of β-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains[J]. Antimicrob Agents Chemother, 2005, 49(11):4733-4738.
[15] YORDANOV D, STRATEVA T. Pseudomonas aeruginosa-a phenomenon of bacterial resistance[J].J Med Microbiol, 2009, 58(9):1133-1148.
[16] SÁENZ Y, ZARAZAGA M, BRIÑAS L, et al. Antibiotic resistance in Escherichia coli isolates obtained from animals,foods and humans in Spain[J]. Int J Antimicrob Agents, 2001, 18(4):353-358.
[17] KONG K F, SCHNEPER L, MATHEE K. Beta-lactam antibiotics:From antibiosis to resistance and bacteriology[J]. APMIS, 2010, 118(1):1-36.
[18] 张珍珍,吴俊伟,魏述永,等.动物源大肠杆菌超广谱β-内酰胺酶与头孢菌素酶基因型分析[J].畜牧兽医学报,2009,40(6):898-903.
ZHANG Z Z, WU J W, WEI S Y,et al. Analysis of genotype of Escherichina coli-produacing ESBLs and Apmc β-lactamases isolated from farm animals[J].Acta Veterinaria et Zootechnica Sinica, 2009,40(6):898-903. (in Chinese)
[19] 叶德举, 罗小民, 沈建华, 等.先导化合物的发现——整合计算机虚拟筛选、化学合成和生物测试方法[J].化学进展, 2007, 19(12):1939-1946.
YE D J, LUO X M, SHEN J H, et al. Discovering potential drug leads via docking, synthesis and bioassay[J]. Progress in Chemistry, 2007, 19(12):1939-1946. (in Chinese)
[20] SHOICHET B K.Virtual screening of chemical libraries[J].Nature,2004,432(7019):862-865.
[21] 侯廷军.计算机辅助药物分子设计方法研究[D].北京:北京大学, 2002.
HOU T J. Study on computer-aided drug molecular design[D]. Beijing:Peking University, 2002. (in Chinese)
[22] SPYRAKIS F, COZZINI P, KELLOGG G E, et al. Docking and scoring in drug discovery[M]//ABRAHAM D J, ROTELLA D P. Burger's medicinal chemistry and drug discovery. Canada:John Wiley & Sons, Inc., 2003:601-684.
[23] WASZKOWYCZ B, CLARK D E, GANCIA E. Outstanding challenges in protein-ligand docking and structure-based virtual screening[J]. Wiley Interdiscip Rev Comput Mol Sci, 2011, 1(2):229-259.
[24] IMPERIO D, GIOVENZANA G B, LAW G I, et al. Synthesis and comparative anion binding profiles of two di-aqua Eu(iii) complexes[J]. Dalton Trans, 2010, 39(41):9897-9903.
[25] FUNFUENHA W, PHAKHODEE W, PATTARAWARAPAN M. Facile and efficient synthesis of C2-symmetrical 1,3,5-triazine polycarboxylate ligands under microwave irradiation[J]. Tetrahedron, 2014, 70(35):5415-5419.
[26] 喻召武. 靶向铜绿假单胞菌粘肽合成酶PBP3的抗菌先导化合物的虚拟筛选与活性研究[D]. 杭州:浙江工商大学, 2016.
YU Z W. Virtual screening and activity studies of antimicrobial lead compounds targeting to penicillin-binding protein 3 of Pseudomonas aeruginosa[D].Hangzhou:Zhejiang Gongshang University, 2016. (in Chinese)
[27] 安艳冬.大肠杆菌PBP1b和铜绿假单胞菌PBP3的表达纯化[D].杭州:浙江工商大学, 2015.
AN Y D. Expression and purification of PBP1B from Escherichia coli and PPBP3 from Pseudomonas aeruginosa[D]. Hangzhou:Zhejiang Gongshang University, 2015. (in Chinese)
[28] 吴可柱,李昆,李爱秀.虚拟筛选技术与新药开发[J].武警医学院学报, 2011, 20(5):415-419.
WU K Z, LI K, LI A X. Virtual screening and new drug discovery[J]. Journal of Armed Police Medical College, 2011, 20(5):415-419. (in Chinese)
[29] RECACHA R, COSTANZO M J,MARYANOFF B E, et al. Crystal structure of human carbonic anhydrase Ⅱ complexed with an anti-convulsant sugar sulphamate[J].Biochem J, 2002, 361(3):437-441.
[30] GUIDO R V, OLIVA G, ANDRICOPULO A D. Virtual screening and its integration with modern drug design technologies[J]. Curr Med Chem, 2008, 15(1):37-46.
[31] LIU A L, CAO H P, DU G H. Drug screening for influenza neuraminidase inhibitors[J].Science in China Ser. C Life Sciences, 2005, 48(1):1-5. |